On February 16, 2022, FDA released a compounding possibility alert describing the prospective hazards affiliated with at-house usage of compounded ketamine nasal spray and a number of other adverse function experiences. The February 2022 compounding hazard inform also offered details about Spravato, which is issue to some Threat Evaluation and Miti